$103M of healthcare reform going to fight chronic disease

The U.S. Department of Health and Human Services (HHS) announced grants to 61 states and communities with more than 120 million residents to fight chronic disease. Created by the Patient Protection & Affordable Care Act, community transformation grants help states and communities tackle the root causes of chronic disease, such as smoking, poor diet and lack of physical activity.

Grantees will use these funds, which total more than $103 million, to transform where their residents live, work, play and go to school so that they can lead healthier lives.

All grantees will work to address the following priority areas: 1) tobacco-free living; 2) active living and healthy eating; and 3) quality clinical and other preventive services, specifically prevention and control of high blood pressure and high cholesterol. Grantees may also focus on creating healthy and safe environments. Grantees will have an additional focus on reducing health disparities.

Grantee activities include:
  • Implementation – Thirty-five grantees will implement proven interventions to help improve health and wellness. Funding amounts range from $500,000 to $10 million depending on population size and scope of project.
  • Capacity Building – Twenty-six grantees will work to build capacity by laying a solid foundation for sustainable community prevention efforts. Funding amounts range from $147,000 to $500,000 depending on population size and scope of project.

Awards are distributed among state and local government agencies, tribal organizations, territories and nonprofit organizations. Awards went to grantees in 36 states, including seven tribal organizations and one territory. These grants are expected to run for five years.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.